Phase 2 Study of the Safety and Efficacy of an Oral Formulation of SPI-1005 for Prevention of Temporary Auditory Threshold Shift
Latest Information Update: 05 Jun 2015
Price :
$35 *
At a glance
- Drugs Ebselen (Primary)
- Indications Hearing loss
- Focus Pharmacodynamics
- Sponsors Sound Pharmaceuticals
- 06 Nov 2013 New trial record
- 05 Nov 2013 Data from this trial will support an active IND with the FDA for ebselen for the prevention and treatment of noise-induced hearing loss, according to a Sound Pharmaceuticals media release.